Cannabis Companies Push F.D.A. to Ease Rules on CBD Products
WASHINGTON — For weeks, the elite of the cannabis trade have been badgering the Food and Drug Administration for a coveted speaking slot on Friday at the agency’s summit on cannabis-derived consumer goods. Blue-chip lawyers were rejected. Scientists were spurned. The agency finally created a complex lottery system to whittle down the list from 400…